Exicure, Inc. (NASDAQ: XCUR)

Exicure, Inc., also known as XCUR, is a biotechnology company operating in the development of nucleic acid therapies. Its main business activities revolve around the creation of gene regulatory and immuno-oncology therapeutics based on its unique and proprietary SNA technology. However, it's important to note that Exicure recently underwent a significant reduction in force, suspended preclinical activities, and halted all research and development as of September 2022, as it explores strategic alternatives to maximize stockholder value.

Exicure generates revenue through the development and licensing of its SNA technology platform, which has been utilized in various therapeutic applications. The company's primary products include its SNA technology platform, which has been instrumental in the development of gene regulatory and immuno-oncology therapeutics.

The biotechnology industry is highly competitive, and Exicure is no exception. The company competes with several large and small biotechnology companies, academic institutions, government agencies, and public and private research institutions. Exicure's competitive advantages include its proprietary SNA technology platform and its expertise in gene regulatory and immuno-oncology therapeutics.

Exicure's customer base is diverse, comprising various biotechnology companies, academic institutions, government agencies, and public and private research institutions. These customers utilize Exicure's products and services for the development of novel therapeutics in the biotechnology and pharmaceutical industries. Some of Exicure's key customers include Biogen Inc., Gilead Sciences, Inc., Novartis AG, Pfizer Inc., and Sanofi SA.

Exicure's SNA technology platform is a proprietary platform that enables the development of gene regulatory and immuno-oncology therapeutics. The platform has been used to develop various therapeutic applications, including gene therapy and immunotherapy. The company's SNA technology has been licensed to several biotechnology companies and academic institutions, generating revenue for Exicure.

Exicure's gene regulatory therapeutics segment focuses on the development of gene therapy products that regulate gene expression. The company has developed several gene therapy products using its SNA technology platform, including its lead product, cavrotolimod. Cavrotolimod is a gene therapy product that has been licensed to a third party for the development of a novel therapeutic application.

Exicure's immuno-oncology therapeutics segment focuses on the development of immunotherapy products that stimulate the immune system to fight cancer. The company has developed several immunotherapy products using its SNA technology platform, including its lead product, SCN9A. SCN9A is a gene therapy product that has been licensed to a third party for the development of a novel therapeutic application.

Exicure's products and services are subject to various government regulations and approvals. The company's products must comply with regulations from the U.S. Food and Drug Administration (FDA) and other regulatory agencies around the world. Exicure's products must also be approved by regulatory agencies before they can be marketed and sold.

The company does not have a dedicated sales and marketing team. Exicure's products and services are marketed through its website and other online channels. The company's products and services are also marketed through partnerships with other biotechnology companies, academic institutions, government agencies, and public and private research institutions.

As of December 31, 2023, Exicure had 6 full-time employees, including finance, human resources, and general management personnel. The company does not have a collective bargaining agreement with its employees and has not experienced any work stoppages.

Exicure was incorporated in 2017 and is headquartered in Chicago, Illinois. The company's common stock is listed on the Nasdaq stock exchange under the ticker symbol XCUR.